BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17544636)

  • 1. The cost of borderline personality disorder: societal cost of illness in BPD-patients.
    van Asselt AD; Dirksen CD; Arntz A; Severens JL
    Eur Psychiatry; 2007 Sep; 22(6):354-61. PubMed ID: 17544636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of borderline personality disorder in Catalonia (Spain).
    Salvador-Carulla L; Bendeck M; Ferrer M; Andión O; Aragonès E; Casas M;
    Eur Psychiatry; 2014 Oct; 29(8):490-7. PubMed ID: 25174269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Societal cost-of-illness in patients with borderline personality disorder one year before, during and after dialectical behavior therapy in routine outpatient care.
    Wagner T; Fydrich T; Stiglmayr C; Marschall P; Salize HJ; Renneberg B; Fleßa S; Roepke S
    Behav Res Ther; 2014 Oct; 61():12-22. PubMed ID: 25113523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and Budget Impact of Specialized Psychotherapy for Borderline Personality Disorder: A Synthesis of the Evidence.
    Wetzelaer P; Lokkerbo J; Arntz A; van Aselt T; Smit F; Evers S
    J Ment Health Policy Econ; 2017 Dec; 20(4):177-190. PubMed ID: 29300704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difficulties in calculating productivity costs: work disability associated with borderline personality disorder.
    van Asselt AD; Dirksen CD; Arntz A; Severens JL
    Value Health; 2008; 11(4):637-44. PubMed ID: 18179672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRO*BPD: effectiveness of outpatient treatment programs for borderline personality disorder: a comparison of Schema therapy and dialectical behavior therapy: study protocol for a randomized trial.
    Fassbinder E; Assmann N; Schaich A; Heinecke K; Wagner T; Sipos V; Jauch-Chara K; Hüppe M; Arntz A; Schweiger U
    BMC Psychiatry; 2018 Oct; 18(1):341. PubMed ID: 30340474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy.
    van Asselt AD; Dirksen CD; Arntz A; Giesen-Bloo JH; van Dyck R; Spinhoven P; van Tilburg W; Kremers IP; Nadort M; Severens JL
    Br J Psychiatry; 2008 Jun; 192(6):450-7. PubMed ID: 18515897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Societal costs of Borderline Personality Disorders: a matched-controlled nationwide study of patients and spouses.
    Hastrup LH; Jennum P; Ibsen R; Kjellberg J; Simonsen E
    Acta Psychiatr Scand; 2019 Nov; 140(5):458-467. PubMed ID: 31483859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of disease in patients eligible for mentalization-based treatment (MBT): quality of life and costs.
    Laurenssen EM; Eeren HV; Kikkert MJ; Peen J; Westra D; Dekker JJ; Busschbach JJ
    Health Qual Life Outcomes; 2016 Oct; 14(1):145. PubMed ID: 27733207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day hospital Mentalization-based treatment versus intensive outpatient Mentalization-based treatment for patients with severe borderline personality disorder: protocol of a multicentre randomized clinical trial.
    Laurenssen EM; Smits ML; Bales DL; Feenstra DJ; Eeren HV; Noom MJ; Köster MA; Lucas Z; Timman R; Dekker JJ; Luyten P; Busschbach JJ; Verheul R
    BMC Psychiatry; 2014 Nov; 14():301. PubMed ID: 25403144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline personality disorder: resource utilisation costs in Ireland.
    Bourke J; Murphy A; Flynn D; Kells M; Joyce M; Hurley J
    Ir J Psychol Med; 2021 Sep; 38(3):169-176. PubMed ID: 34465404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The societal cost of treatment-seeking patients with borderline personality disorder in Germany.
    Wagner T; Assmann N; Köhne S; Schaich A; Alvarez-Fischer D; Borgwardt S; Arntz A; Schweiger U; Fassbinder E
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):741-752. PubMed ID: 34605983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of Dialectical Behavior Therapy (DBT) in an outpatient clinic for borderline personality disorders - impact of medication use and treatment costs].
    Richter C; Heinemann B; Kehn M; Steinacher B
    Psychiatr Prax; 2014 Apr; 41(3):148-52. PubMed ID: 23733226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mental health service utilization among borderline personality disorder patients inpatient].
    Cailhol L; Thalamas C; Garrido C; Birmes P; Lapeyre-Mestre M
    Encephale; 2015 Apr; 41(2):115-22. PubMed ID: 25526809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based cost-offset estimation for the treatment of borderline personality disorder: projected costs in a currently running, ideal health system.
    Wunsch EM; Kliem S; Kröger C
    Behav Res Ther; 2014 Sep; 60():1-7. PubMed ID: 25014129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands.
    Soeteman DI; Verheul R; Meerman AM; Ziegler U; Rossum BV; Delimon J; Rijnierse P; Thunnissen M; Busschbach JJ; Kim JJ
    J Clin Psychiatry; 2011 Jan; 72(1):51-9. PubMed ID: 21034679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of psychotherapy for cluster B personality disorders.
    Soeteman DI; Verheul R; Delimon J; Meerman AM; van den Eijnden E; Rossum BV; Ziegler U; Thunnissen M; Busschbach JJ; Kim JJ
    Br J Psychiatry; 2010 May; 196(5):396-403. PubMed ID: 20435967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs associated with attempted suicide among individuals with bipolar disorder.
    Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
    J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to deal with cost differences at baseline.
    van Asselt AD; van Mastrigt GA; Dirksen CD; Arntz A; Severens JL; Kessels AG
    Pharmacoeconomics; 2009; 27(6):519-28. PubMed ID: 19640014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.